<DOC>
	<DOCNO>NCT02322814</DOCNO>
	<brief_summary>This multistage , randomize , Phase II , double-blind , multicenter , placebo-controlled trial evaluate safety tolerability estimate efficacy cobimetinib + paclitaxel versus placebo + paclitaxel patient metastatic locally advanced , triple-negative adenocarcinoma breast receive prior systemic therapy metastatic breast cancer ( MBC ) . An open-label safety run-in stage combination cobimetinib + paclitaxel undergo Internal Safety Review start enrollment patient expansion double-blind stage study . Patients may continue study treatment development progressive disease , unacceptable toxicity , and/or consent withdrawal . The target sample size 12 patient safety run-in stage approximately 100 patient expansion stage .</brief_summary>
	<brief_title>A Study Cobimetinib Combination With Paclitaxel First-line Treatment Patients With Metastatic Triple-negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically confirm estrogen receptor ( ER ) negative , progesterone receptor ( PR ) negative , human epidermal growth factor 2 ( HER2 ) negative adenocarcinoma breast measurable metastatic locally recurrent disease Locally recurrent disease must amenable resection curative intent Measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) , v1.1 Adequate hematologic end organ function Agreement use highly effective contraceptive method state protocol Known HER2 , ER , PRpositive breast cancer local laboratory assessment Any prior chemotherapy , hormonal , targeted therapy , inoperable locally advanced metastatic triplenegative breast cancer ( mTNBC ) Any systemic anticancer therapy within 3 week prior Cycle 1 , Day 1 Any radiation treatment metastatic site within 28 day Cycle 1 , Day 1 Major surgical procedure , open biopsy , significant traumatic injury within 30 day prior Cycle 1 , Day 1 anticipation need major surgical procedure course study Prior exposure experimental treatment target Raf , MEK , MAPK pathway Brain metastasis ( symptomatic nonsymptomatic ) treat previously , progressive , require type therapy ( e.g. , radiation , surgery , steroid ) control symptom brain metastasis within 60 day prior first study treatment dose History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment/central serous chorioretinopathy ( CSCR ) , retinal vein occlusion ( RVO ) , neovascular macular degeneration History clinically significant cardiac dysfunction Pregnancy ( positive serum pregnancy test ) lactation Uncontrolled serious medical psychiatric illness Active infection require intravenous ( IV ) antibiotic Cycle 1 , Day 1 Patients history hypersensitivity reaction paclitaxel drug formulate CremophorÂ® EL ( polyoxyethylated castor oil )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>